Recipharm teams up with Hadasit

Partnership created with the goal of delivering seamless chemical and clinical services

Register for free to listen to this article
Listen with Speechify
STOCKHOLM & JERUSALEM—Recipharm, a global contract development and manufacturing organization (CDMO), has partnered with Hadasit Medical Research Services and Development to offer combined clinical, biological and chemical services. Located in Israel, Hadasit, which is a wholly owned subsidiary of Hadassah Medical Organization (HMO), offers a variety of research, development and consulting services to customers, primarily in the Middle East.
Hadasit provides clinical-oriented R&D services that can assist customers from the point of early preclinical development up to regulatory approval, saving time and money. Recipharm’s facility in Israel has partnered with the firm as part of its growth plans in the market, and to enable a more seamless customer experience as pharmaceutical products progress through clinical phases. Recipharm was established in Israel in 2015, and since then the business has grown to serve more than 50 customers, primarily in Israel and the United States.
Dr. Sylvia Kachalsky, site manager at Recipharm in Israel, commented regarding the partnership: “Developing a drug involves chemical, biological and clinical expertise. Our partnership with Hadasit means we can offer these services more efficiently and manage projects seamlessly from development to clinic.”
“The partnership will support business growth in Israel, giving Recipharm access to the majority of the clinical trials taking place in the country. While the field of chemistry services is relatively new to this market, the growth potential is substantial, with more than 800 biotech companies in Israel and the number and size of these companies continuing to grow,” continued Kachalsky. “By collaborating with one of the most prestigious hospitals in the region and its commercial arm, we believe this will support our goal to become the most trusted CDMO in the region.”
Hadasit brings a number of specialist services to the partnership, including in-vitro analysis in various models, access to and analysis of human samples, in-vivo models for multiple medical conditions, input regarding medical indications and the conducting of clinical trials at all phases.
Dr. Tamar Raz, CEO at Hadasit, said, “Through the partnership, we will be able to offer a full service for the synthesis and testing of compounds. Working with Recipharm, our team will gain professional input regarding the compounds that Hadassah researchers and Hadasit companies are developing, including synthesis and medicinal chemistry challenges. We are looking forward to a mutually beneficial long-term partnership which will ultimately help both companies to grow and support the pharmaceutical industry in Israel.”
In other Recipharm news, the CDMO announced on May 24 that it has established a dedicated taskforce to manage the potential impact of Brexit on its organization. With less than a year until the United Kingdom exits the European Union (EU), Recipharm is focused on managing the transition with minimal impact to its operations and customers. The formation of the “Brexit taskforce” will have Recipharm prioritizing its preparations and investing in the necessary capabilities and equipment within its U.K. and European facilities, in order to ensure seamless operations post-March 2019.
“While many stakeholders in the pharma industry are campaigning for a ‘soft’ exit from the EU, there is a risk that the complexity of the regulatory landscape will increase dramatically if a ‘hard’ Brexit takes place,” commented Thomas Beck, senior vice president of quality management at Recipharm. “Consequently, we are preparing for all eventualities. Recipharm’s presence in both the U.K. and mainland Europe means we are well positioned to support our customers post-Brexit. We are also adept at streamlining processes across geographies and dealing with third-party importations into Europe due to our global facilities.”
With around 5,000 employees and development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the United Kingdom and the United States, Recipharm may be wise to be thinking ahead about the potential of Brexit to impact its operations. To strengthen its organization ahead of Brexit, Recipharm has plans to recruit more staff in laboratory and regulatory roles to meet the additional analytical, release testing and administration requirements that are expected.
“Brexit has the potential to bring about additional resource demands. We are focused on ensuring our team is equipped to handle the potential challenges so that our customers continue to receive the same level of service,” said Beck. “We also expect to see a greater demand for outsourced manufacturing services from U.K.-based marketing authorization holders wishing to supply to Europe and are preparing our team to meet this demand. We firmly believe that the challenge needs to be faced in a pragmatic way, and have been liaising with both the EMA and relevant politicians to communicate that the finer details of Brexit and the implications on our industry need to be discussed as a matter of priority.”

Published In:

Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

DDN Magazine May 2024

Latest Issue  

• Volume 20 • Issue 3 • May 2024

May 2024

May 2024 Issue